GIST

PURPOSE: Although genetic p53 aberrations are correlated with the prognosis of various types of cancer, their prognostic relevance is currently unclear in patients with gastrointestinal stromal tumors (GISTs) of the small intestine. METHODS: Between 1994 and 2008, 113 patients with resected localized GISTs of the small intestine were included in this analysis. Patients who received pre- and/or postoperative chemotherapy were excluded. p53 overexpression was assessed by immunohistochemical staining and defined as expression in >10 % of tumor cells...

Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. Improvements in understanding the molecular pathogenesis of GIST have resulted in novel treatment strategies combining surgery with tyrosine kinase inhibitors (TKIs). Metastasectomy in carefully selected patients who have stable or responsive disease on imatinib should be considered in the multidisciplinary setting. We review existing data on surgical cytoreduction in metastatic GIST while on targeted therapy and compare outcomes with either treatment alone...

Despite being the most common sarcoma of the gastrointestinal tract, gastrointestinal stromal tumor (GIST) has been widely recognized as a unique entity for just over a decade. The advent of tyrosine kinase inhibitors has revolutionized the diagnosis and treatment of GIST. Although surgery remains the only chance for cure, multimodal treatment that includes molecular therapy continues to develop. Optimal management of GIST requires careful radiographic, pathologic, medical, and surgical care, emphasizing the need for a multidisciplinary approach...